Back to all discussions

In Vivo Generation of Lung and Thyroid Tissues from Embryonic Stem Cells Using B

This is great advancement is stem cell science. Now we need to progress to human studies.

Rationale: The regeneration and replacement of lung cells or tissues from induced pluripotent stem cell– or embryonic stem cell–derived cells represent future therapies for life-threatening pulmonary disorders but are limited by technical challenges to produce highly differentiated cells able to maintain lung function. Functional lung tissue–containing airways, alveoli, vasculature, and stroma have never been produced via directed differentiation of embryonic stem cells (ESCs) or induced pluripotent stem cells. We sought to produce all tissue components of the lung from bronchi to alveoli by embryo complementation.

Conclusions: Lung and thyroid tissues were generated in vivo from ESCs by blastocyst complementation.

  1. I shouldn't say only murine. This regenerative property has also been found in porcine species too. They just don't understand the human regenerative property yet. That's why funding should go for that initiative instead of more drugs that just maintain this disease.

    1. HI. me_for_president. Thank you for the link. It certainly does look like a very promising study. I would imagine stem cells will be studied on humans at some point in the near future, so long as other similar studies show equal promise and safety. If it is studied on humans, would you be interested in participating? Just curious. John. Community Moderator.

      1. The thing that makes my first post different is the the stem cells were administered with blastocyst complementation.

        This enabled a more composite array of regeneration then had been previously performed.

        Alas, this has only been found to be true in murine species as of yet.

      2. Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)
        Patients with advanced chronic obstructive pulmonary disease — characterized by a forced expiratory volume in 1 second (FEV1) value between 20% and 49% — who are already receiving maximal medical therapy are being enrolled in a pilot study. The study subjects receive MSCs from healthy young donors and are followed for one year. Jorge M. Mallea, M.D., Pulmonary Medicine at Mayo Clinic's campus in Jacksonville, Florida. is the principal investigator for this trial.

        Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD).

        This is that to which I was referring.

    or create an account to reply.